期刊
CLINICAL MICROBIOLOGY AND INFECTION
卷 18, 期 -, 页码 93-99出版社
ELSEVIER SCI LTD
DOI: 10.1111/j.1469-0691.2012.03971.x
关键词
Cancer; influenza; pneumococci; solid organ transplantation; stem cell transplantation; vaccination
资金
- VICAL Inc
- Astellas Pharma
- GSK
- Merck
Clin Microbiol Infect 2012; 18 (Suppl. 5): 9399 Abstract Vaccination of immunocompromised patients is challenging both regarding efficacy and safety. True efficacy data are lacking so existing recommendations are based on immune responses and safety data. Inactivated vaccines can generally be used without risk but the patients who are most at risk for infectious morbidity and mortality as a result of their severely immunosuppressed state are also those least likely to respond to vaccination. However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally recommended. Live vaccines must be used with care because the risk for vaccine-associated disease exists.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据